Previous 10 | Next 10 |
2023-11-09 10:00:37 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector a...
2023-11-08 22:15:05 ET Assertio Holdings Inc. (ASRT) Q3 2023 Earnings Conference Call November 8, 2023, 04:30 PM ET Company Participants Matt Kreps - Darrow Associates, IR Dan Peisert - President and CEO Ajay Patel - SVP & Chief Accounting Officer Paul Sc...
2023-11-08 16:04:54 ET More on Assertio Holdings Assertio Holdings: Uncovering A Tapestry Of Trading Opportunities From This Oversold Ticker Growth And Pain Make Assertio A Deep Value Buy Assertio's Financial Horizon Amidst Indocin Generic Entry Assertio Hold...
Closed Spectrum Acquisition on July 31, 2023, which diversifies and extends portfolio duration Cash balance at September 30, 2023 of $76.9 million Announces Management Updates LAKE FOREST, Ill., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Asserti...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Assertio Holdings Inc. (ASRT) is expected to report $0.13 for Q3 2023
LAKE FOREST, Ill., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it will release third quarter 2023 financial...
2023-10-15 04:41:12 ET Summary Assertio Holdings has undergone a significant transformation in its business model, reducing debt and exiting the opioid business. The company's recent performance has shown strong growth, with increased net product sales and improved gross margin. ...
2023-09-12 08:00:00 ET Summary Assertio Holdings has experienced extreme price volatility, but the current price presents a buying opportunity. The company has diversified its pharmaceutical portfolio and improved its financial position, positioning it for future growth. Risks...
2023-09-01 19:55:44 ET Summary Assertio's Q2 earnings report showed a 16.7% annual growth in revenue, exceeding forecasts by $1.16M. The company's profitability and liquidity are promising, with a positive operating cash flow and substantial cash on hand. Assertio faces a sign...
News, Short Squeeze, Breakout and More Instantly...
Assertio Therapeutics Inc. Company Name:
ASRT Stock Symbol:
NASDAQ Market:
Assertio Therapeutics Inc. Website:
2024-07-03 07:15:03 ET H.C. Wainwright analyst issues BUY recommendation for ASRT on July 3, 2024 06:04AM ET. ASRT was trading at $1.15 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendati...
LAKE FOREST, Ill., June 05, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that Ajay Patel, Chief...
LAKE FOREST, Ill., May 29, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that its Board of...